Continuous Infusion of Vincristine-Doxorubicin with Bolus of Dexamethasone(VAD) Alternated with CHEP in the Treatment of Patients over 60 Years Old with Aggressive Non-Hodgkin's Lymphoma

References

• Cooper I. A., Wolf M. M., Robertson T. I., et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Journal of Clinical Oncology 1994; 12: 769–778
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Gordon L. I., Harrington D., Andersen J., et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. New England Journal of Medicine 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Linch D. C., Vaughan Hudson B., Hancock B. W., et al. A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. British Journal of Cancer 1996; 74: 318–322
   PubMed Web of Science ®Google Scholar
• Goss P., Burkes R., Rudinskas L., et al. A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients. Leukemia and Lymphoma 1995; 18: 145–152
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P., Chastang C., Herrera A., et al. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. American Journal of Medicine 1987; 83: 1075–1079
   PubMed Web of Science ®Google Scholar
• Ansell S. M., Falkson G., van der Merwe R., Uys A. Chronological age is a multifactorial prognostic variable in patients with non-Hodgkin's lymphoma. Annals of Oncology 1992; 3: 45–50
   PubMed Web of Science ®Google Scholar
• Dixon D. O., Neilan B., Jones S. E., et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. Journal of Clinical Oncology 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Peters F. P., Ten Haaft M. A., Schouten H. C. Intermediate and high grade non Hodgkin's lymphoma in the elderly. Leukemia and Lymphoma 1999; 33: 243–252
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Serraino D., et al. Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study. Journal of Clinical Oncology 1988; 6: 1708–1713
   PubMed Web of Science ®Google Scholar
• Vose J. M., Armitage J. O., Weisenburger D. D., et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Grogan L., Corbally N., Dervan P. A., Byrne A., Carney D. N. Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin-based regimens. Annals of Oncology 1994; 5: 47–51
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Potter J. F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. Journal of the American Geriatry Society 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Bellesi G., Rigacci L., Alterini R., et al. A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly. Leukemia and Lymphoma 1996; 20: 475–480
   PubMed Web of Science ®Google Scholar
• Bertini M., Freilone R., Vitolo U., et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Annals of Oncology 1994; 5: 895–900
   PubMed Web of Science ®Google Scholar
• Bessell E. M., Coutts A., Fletcher J., et al. Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate-or high-grade histology. European Journal of Cancer 1994; 9: 1337–1341
   Web of Science ®Google Scholar
• Martelli M., Guglielmi C., Coluzzi S., et al. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1993; 11: 2362–2369
   PubMed Web of Science ®Google Scholar
• McMaster M. L., Johnson D. H., Greer J. P., et al. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 1991; 67: 1487–1492
   PubMed Web of Science ®Google Scholar
• O'Reilly S. E., Klimo P., Connors J. M. Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. Journal of Clinical Oncology 1991; 9: 741–747
   PubMed Web of Science ®Google Scholar
• Salvagno L., Contu A., Bianco A., et al. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Annals of Oncology 1992; 3: 833–837
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P., Tertian G., Herrera A., Brousse N., Peuchmaur M. Treatment of aggressive non-Hodgkin's lymphoma in aged patients with a combination of methyl-GAG, etoposide and prednimustine. Bulletin du Cancer 1990; 77: 449–452
   PubMed Web of Science ®Google Scholar
• Tigaud J. D., Demolombe S., Bastion Y., Bryon P. A., Coiffier B. Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: a phase II study. Hematological Oncology 1991; 9: 225–233
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Errante D., et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. Journal of Clinical Oncology 1992; 10: 228–236
   PubMed Web of Science ®Google Scholar
• Sonneveld P., de Ridder M., van der Lelie H., et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Journal of Clinical Oncology 1995; 13: 2530–2539
   PubMed Web of Science ®Google Scholar
• Meyer R. M., Browman G. P., Samosh M. L., et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology 1995; 13: 2386–2393
   PubMed Web of Science ®Google Scholar
• Tirelli U., Errante D., Van Glabbeke M., et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. Journal of Clinical Oncology 1998; 16: 27–34
   PubMed Web of Science ®Google Scholar
• Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine 1984; 310: 1353–1356
   PubMed Web of Science ®Google Scholar
• Chabner B. A., Wilson W. Reversal of multidrug resistance. Journal of Clinical Oncology 1991; 9: 4–6
   PubMed Web of Science ®Google Scholar
• Eichholtz-Wirth H. Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro. British Journal of Cancer 1980; 41: 886–891
   PubMed Web of Science ®Google Scholar
• Hortobagyi G. N., Frye D., Buzdar A. U., et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989; 63: 37–45
   PubMed Web of Science ®Google Scholar
• Anderson H., Scarffe J. H., Lambert M., et al. VAD chemotherapy—toxicity and efficacy—in patients with multiple myeloma and other lymphoid malignancies. Hematological Oncology 1987; 5: 213–222
   PubMed Web of Science ®Google Scholar
• Dalton W. S., Grogan T. M., Meltzer P. S., et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. Journal of Clinical Oncology 1989; 7: 415–424
   PubMed Web of Science ®Google Scholar
• Gressin R., Legouffe E., Leroux D., et al. Treatment of mantle-cell lymphomas with the VAD +/-chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation. Annals of Oncology 1997; 8: 103–106
   PubMed Web of Science ®Google Scholar
• National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Research 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Hryniuk W. The importance of dose intensity in the outcome of chemotherapy. Lippincott, ed. Advances in Oncology, S Hellman, V De Vita, S Rosenberg, Philadelphia 1988; 121–141
   Google Scholar
• Kaplan EM M. P. Nonparametric estimation from incomplete observation. Journal of American Statistic Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto R., Pike M. C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. British Journal of Cancer 1976; 34: 585–612
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. Journal of Royal Statistic Society 1972; 34: 187–220
   Google Scholar
• Zagonel V., Babare R., Merola M. C., et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Annals of Oncology 1994; 5: 127–132
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Pavone E., Storti S., et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89: 3974–3979
   PubMed Web of Science ®Google Scholar
• Guerci A., Lederlin P., Reyes E, et al. Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte. Annals of Oncology 1996; 7: 966–969
   PubMed Web of Science ®Google Scholar
• Alexanian R., Barlogie B. New treatment strategies for multiple myeloma. American Journal of Hematology 1990; 35: 194–198
   PubMed Web of Science ®Google Scholar
• Jackson D. V., Jr., Bender R. A. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Research 1979; 39: 4346–4349
   PubMed Web of Science ®Google Scholar
• Legha S. S., Benjamin R. S., Mackay B., et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Annals of Internal Medecine 1982; 96: 133–139
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Walters R. S., Keating M. J., et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard-and high-risk acute lymphocytic leukemia. Journal of Clinical Oncology 1990; 8: 994–1004
   PubMed Web of Science ®Google Scholar
• Delain M., Linassier C., Petitdidier C., et al. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma. Journal of Clinical Oncology 1994; 12: 2706–2713
   PubMed Web of Science ®Google Scholar
• Zinzani P., Storti S., Zaccaria A., et al. Elderly agressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94: 33–38
   PubMed Web of Science ®Google Scholar
• Zinzani P., Storti S., Zaccaria A., et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Coiffier B., Brousse N., Peuchmaur M., et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Annals of Oncology 1990; 1: 45–50
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C., Gaulard P., Lepage E., et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76–82
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Vose J. M., Linder J., et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1989; 7: 1783–1790
   PubMed Web of Science ®Google Scholar
• Kwak L. W., Wilson M., Weiss L. M., et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. Journal of Clinical Oncology 1991; 9: 1426–1431
   PubMed Web of Science ®Google Scholar
• Melnyk A., Rodriguez A., Pugh W. C., Cabanillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514–4520
   PubMed Web of Science ®Google Scholar